Pathophysiology of severe asthma : What are the molecular targets for biotherapies?

Publié en janvier 2023 BULLETIN DE L ACADEMIE NATIONALE DE MEDECINE

USTEKINUMAB MODULATES IL-12 AND IL-23-RELATED CELL TYPE-SPECIFIC INFLAMMATORY TRANSCRIPTIONAL STATES IN ULCERATIVE COLITIS INDUCTION THERAPY

BULLETIN DE L ACADEMIE NATIONALE DE MEDECINE

Publication précédente

Dupilumab long-term efficacy in patients with asthma with or without comorbid chronic rhinosinusitis/nasal polyposis enrolled in LIBERTY ASTHMA TRAVERSE from phase 2b study

BULLETIN DE L ACADEMIE NATIONALE DE MEDECINE

Publication suivante